A5085060318- Lymphoma Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Viral-associated cancers and disorders
- Moyamoya disease diagnosis and treatment
- CNS Lymphoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- Extracellular vesicles in disease
- CAR-T cell therapy research
- RNA Research and Splicing
- Venomous Animal Envenomation and Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- HIV-related health complications and treatments
- Immune Cell Function and Interaction
- Blood Coagulation and Thrombosis Mechanisms
- HIV Research and Treatment
- Reproductive System and Pregnancy
- Vitamin K Research Studies
The Maria Sklodowska-Curie National Research Institute of Oncology
2014-2025
Non-small cell lung cancer (NSCLC) accounts for 80% of cancers, the leading cause mortality. microRNAs (miRNA, miR) have emerged as important components carcinogenesis and promising biomarkers. We aimed to analyse global plasma miRs in NSCLC patients before at least one year after tumour resection. Plasma was collected from peripheral blood 24 donors without surgery (n=36) 1 (n=12). Next-generation sequencing (NGS)-based miR profiling performed. Patients were followed-up 4 12 years assess...
Primary central nervous system lymphoma (PCNSL) is a rare, highly aggressive, extranodal form of non-Hodgkin lymphoma, predominantly diagnosed as primary diffuse large B-cell the (CNS DLBCL). Fast and precise diagnosis PCNSL critical yet challenging. microRNAs, important regulators in physiology pathology are potential biomarkers. In 131 patients with CNS DLBCL non-malignant brain lesions (n-ML), miR-21, miR-19b miR-92a, miR-155, miR-196b, miR-let-7b, miR-125b, miR-9 were examined by RT-qPCR...
Fast and reliable differential diagnosis of Burkitt lymphoma (BL) vs. diffuse large B cell (DLBCL) is major importance for therapeutic decisions patient outcome. Aggressive non-Hodgkin lymphomas (B-NHLs) that do not belong to the abovementioned entities were categorized by current WHO classification as "B-cell lymphoma, unclassifiable, with features intermediate between DLBCL BL" (DLBCL/BL). We have recently described a DLBCL/BL subgroup recurrent chromosome 11q aberrations, resembling BL...
The diagnosis of primary central nervous system (CNS) lymphoma, which is predominantly the diffuse large B-cell lymphoma type (CNS DLBCL), challenging. MicroRNAs (miRs) are gene expression-regulating non-coding RNAs that potential biomarkers. We aimed to distinguish miR expression patterns differentiating CNS DLBCL and non-malignant diseases with tumor presentation (n-ML). Next generation sequencing-based profiling cerebrospinal fluids (CSFs) brain tumors was performed. Sample...
High-grade B-cell lymphoma with 11q aberration (HGBCL-11q) is a rare germi-nal centre characterised by typical gain/loss pattern on chromo-some but without MYC translocation. It shares some features Burkitt (BL), HGBCLs and germinal centre-derived diffuse large lym-phoma, not otherwise specified (GCB-DLBCL-NOS). Since microRNA expression in HGBCL-11q remains unknown, we aimed to identify compare the mi-croRNA profiles HGBCL-11q, BL GCB-DLBCL-NOS. Next-generation sequencing (NGS)-based profiling of (
Burkitt-like lymphoma with 11q aberration (BLL,11q) is a new entity of germinal center (GCB)-derived, highly aggressive B-cell lymphoma. Clinically and pathomorphologically, BLL,11q resembles Burkitt (BL), but it lacks MYCrearrangements presents proximal gains distal losses in chromosome 11. In the updated 2017 WHO classification, has been recognized as provisional entity. could be promoted to definite lymphomas for this purpose necessary publish many cases possible, more molecular studies...
The complete amino acid sequence (582 residues), positions of the twelve disulfide bridges and three carbohydrate substituents, position identity ten vitamin Independent γ-carboxyglutamic (Gla) residues has been determined. A synthetic substrate specific for Factor Xa developed on basis prothrombin structure. primary structure hirudin nearly completed suggests a mechanism its thrombin specificity. pro-part contains two 83 residue regions with identical disulfide-bridge pattern 31 identities....